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Key messages
What is already known about this subject?
 ► Patients with psoriatic arthritis (Psa) often cycle 
among tumour necrosis factor inhibitors (tnFis), 
although data regarding the effectiveness of tnFi 
cycling in clinical practice are inconclusive.
 ► as biologics with alternative mechanisms of action 
become available, it is important to understand the 
persistence of tnFi use among tnFi-naive versus 
tnFi-experienced patients and to characterise those 
who continue versus discontinue their tnFis in order 
to better inform treatment decisions for patients with 
Psa.
What does this study add?
 ► in this real-world analysis of US patients with Psa, 
tnFi-experienced patients were more likely to dis-
continue or switch their index tnFi and had a short-
er time to discontinuation compared with tnFi-naive 
patients.
 ► Patients who discontinued their index tnFi by the 
first follow-up visit were more likely to be female 
and showed a trend toward higher disease activi-
ty and worse patient-reported outcomes compared 
with those who continued.
How might this impact on clinical practice?
 ► these results may help inform treatment decisions 
when selecting later lines of therapy for patients 
with Psa.
AbstrAct
Objective to examine patterns of tumour necrosis factor 
inhibitor (tnFi) use in tnFi-naive and tnFi-experienced 
patients with psoriatic arthritis (Psa) in the USa.
Methods all patients aged ≥18 years with Psa enrolled 
in the corrona Psoriatic arthritis/Spondyloarthritis 
registry who initiated a tnFi (index therapy) 
between March 2013 and January 2017 and had ≥1 
follow-up visit were included. times to and rates of 
discontinuation/switch of the index tnFi were compared 
between tnFi-naive and tnFi-experienced cohorts. 
Patient demographics and disease characteristics at the 
time of tnFi initiation (baseline) were compared between 
cohorts and between patients who continued versus 
discontinued their index tnFi by the first follow-up visit 
within each cohort.
Results this study included 171 tnFi-naive and 147 
tnFi-experienced patients (total follow-up, 579.2 person-
years). Overall, 75 of 171 tnFi-naive (43.9%) and 80 of 
147 tnFi-experienced (54.4%) patients discontinued their 
index tnFi; 33 of 171 (19.3%) and 48 of 147 (32.7%), 
respectively, switched to a new biologic. tnFi-experienced 
patients had a shorter time to discontinuation (median, 
20 vs 27 months) and were more likely to discontinue 
(p=0.03) or switch (p<0.01) compared with tnFi-naive 
patients. among those who discontinued, 49 of 75 tnFi-
naive (65.3%) and 59 of 80 tnFi-experienced (73.8%) 
patients discontinued by the first follow-up visit; such 
patients showed a trend towards higher baseline disease 
activity compared with those who continued.
Conclusions the results of this real-world study can help 
inform treatment decisions when selecting later lines of 
therapy for patients with Psa.
InTROduCTIOn
Psoriatic arthritis (PsA) is a chronic, 
immune-mediated rheumatic disease that 
affects the musculoskeletal system, skin and 
nails.1 2 The symptoms of PsA are diverse and 
may include axial skeletal disorders, nail and 
skin changes, peripheral joint inflammation, 
enthesitis and/or dactylitis.1–3 Patients with 
PsA also have increased risk of developing a 
number of comorbidities, including hyperten-
sion, hyperlipidaemia, cardiovascular disease, 
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type 2 diabetes mellitus, Crohn’s disease, chronic obstruc-
tive pulmonary disease and depression, compared with the 
general population.3–5 PsA is frequently associated with 
psoriasis; an estimated 6%–42% of patients with psoriasis 
have or will develop PsA,1 6 7 while studies suggest that 
10%–40% of patients with psoriasis may have undiagnosed 
PsA.8 9 The clinical heterogeneity of symptoms and poten-
tial burden of comorbidities can complicate the diagnosis 
and treatment of PsA.3 10
Symptomatic treatment of PsA typically includes 
non-steroidal anti-inflammatory drugs and corticoste-
roids.11 12 For patients with active PsA, disease-modifying 
antirheumatic drugs, such as methotrexate or biologics, 
may be necessary for disease control.11 12 Tumour 
necrosis factor inhibitors (TNFis) have traditionally 
been the first choice of biologic agent for patients with 
refractory PsA.12–14 The efficacy and safety of TNFis 
for the treatment of PsA have been demonstrated in 
clinical trials.15–19 However, previous real-world studies 
have shown that approximately 20%–40% of patients 
with PsA who initiate a TNFi may discontinue due to 
primary or secondary loss of efficacy, adverse effects 
or other reasons.20 21 For patients who do not respond 
to a particular TNFi, switching to another TNFi may 
be effective and is a treatment option based on the 
published literature and experience in clinical prac-
tice.12–14 21
European registry studies have shown mixed outcomes 
with respect to the effectiveness and persistence of 
TNFis in patients with PsA who received first-line 
versus second-line TNFis, with some studies showing 
better outcomes in patients who switched TNFis and 
others showing no difference between treatment 
lines or poorer response and persistence in patients 
who initiated a second-line versus first-line TNFi.20–25 
A prospective, observational study of patients with 
PsA in southern Sweden showed moderate improve-
ment in disease activity following the first switch of 
TNFi, but poorer response in patients who switched a 
second time.26 A previous study using US claims data 
showed that patients who initiated a first-line TNFi had 
longer persistence compared with those who initiated 
a second-line TNFi; however, this study did not assess 
patient factors that may be associated with persistence, 
such as disease activity and patient-reported outcomes 
(PROs) at initiation, or reasons for discontinuation.27
Few studies have characterised patients with PsA who 
continue versus discontinue a TNFi based on line of TNFi 
therapy in real-world settings in the USA. A previous study 
of patients with PsA enrolled in the US-based Corrona 
Registry observed greater persistence with TNFi therapy 
among biologic-naive patients compared with biologic-ex-
perienced patients; baseline patient characteristics asso-
ciated with non-persistence included high disease activity 
and longer disease duration in both patient populations 
as well as prior non-biologic disease-modifying antirheu-
matic drug use and greater skin involvement among 
biologic-experienced patients.28 However, this study was 
conducted in patients enrolled in the Corrona Registry 
who initiated a TNFi between October 2002 and March 
2013, prior to the approval of biologics with alternative 
mechanisms of action (MOAs) for the treatment of PsA 
and before the launch of the Corrona Psoriatic Arthritis/
Spondyloarthritis (PsA/SpA) Registry (March 2013), 
which focuses on a unique cohort of patients with PsA/
SpA. The introduction of newer biologics with alterna-
tive MOAs has provided additional treatment options for 
first-line biologic therapy and for patients who have an 
inadequate response to a TNFi. The availability of these 
biologics with new MOAs may change biologic prescribing 
patterns and patient preferences in clinical practice; 
thus, reassessment of treatment patterns is needed as the 
therapeutic landscape continues to expand.
To better inform decisions regarding choice of 
biologic therapy for patients with PsA in clinical prac-
tice, it is important to understand the persistence of 
TNFi use among TNFi-naive patients compared with 
those who cycle among multiple TNFis and to char-
acterise those who continue versus discontinue a first 
versus second or later line of TNFi therapy. There-
fore, the objective of this study was to examine patient 
characteristics and patterns of TNFi use in TNFi-naive 
versus TNFi-experienced patients with PsA enrolled in 
the US Corrona PsA/SpA Registry.
MeTHOds
study population
The Corrona PsA/SpA Registry (NCT02530268) is a 
large, independent, prospective, observational cohort of 
patients diagnosed with PsA or SpA by a rheumatologist. 
The registry includes patients recruited by 43 partici-
pating rheumatologists from 35 private and academic 
practice sites across 22 states in the USA. Follow-up data 
collection occurs approximately every 6 months using 
questionnaires completed by patients and their treating 
rheumatologists. As of December 2017, data on 2526 
patients with PsA/SpA had been collected. The Corrona 
PsA/SpA Registry includes information on 10 767 patient 
visits and approximately 5928 patient-years of follow-up 
observation time, with a mean duration of follow-up of 
3.0 years (median, 3.3 years).
This study included all patients aged ≥18 years 
enrolled in the Corrona PsA/SpA Registry who were 
diagnosed with PsA, initiated a TNFi (index therapy) 
between March 2013 and January 2017 and had ≥1 
follow-up visit after TNFi initiation. Patients were 
assigned to a cohort based on prior biologic use (TNFi 
naive: no prior TNFi or other biologic; TNFi experi-
enced: ≥1 prior TNFi without use of a prior non-TNFi 
biologic) and followed until discontinuation of the 
index biologic or the end of the study period. Patients 
within the TNFi-naive and TNFi-experienced cohorts 
were stratified by continuation or discontinuation of 
the index TNFi by the first follow-up visit. Patients in 
the continued group were those who were still receiving 
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Figure 1 Patient disposition. The total follow-up period 
included 579.2 person-years, with a mean (SD) follow-up 
of 21.9 (9.6) months and median (IQR) follow-up of 23.0 
(15.0) months. Patients included in the discontinued groups 
were those who switched to a new biologic (TNFi naive, 
n=33; TNFi experienced, n=48) or who discontinued without 
switching (TNFi naive, n=42; TNFi experienced, n=32). PsA, 
psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour 
necrosis factor inhibitor.
the index TNFi at the first follow-up visit; patients in the 
discontinued group were those who switched from the 
index TNFi to a different TNFi or who discontinued the 
index TNFi without switching by the first follow-up visit. 
For patients who switched TNFis during follow-up, only 
the first TNFi initiation was included in the analysis.
All participating investigators were required to obtain 
full board approval for conducting non-interventional 
research involving human subjects with a limited data set. 
All research was conducted in compliance with the Helsinki 
Declaration of 1964 and all later amendments. All registry 
subjects were required to provide written informed consent 
and authorisation prior to participating.
Outcomes and assessments
Data were collected using questionnaires completed by 
patients and their treating rheumatologists at office visits. 
Data collected at the time of TNFi initiation (baseline) 
included patient demographics, clinical characteristics, 
laboratory measurements, disease activity measures and 
PROs; baseline characteristics were compared between 
TNFi-naive and TNFi-experienced patients and between 
those who continued versus discontinued their index 
TNFi by the first follow-up visit.
Time to discontinuation (with or without switching) 
and time to switch to a new biologic over the total 
follow-up period were reported for patients who 
discontinued their index TNFi in the overall popu-
lation and in the TNFi-naive and TNFi-experienced 
cohorts. Provider-reported reasons for discontinuation 
or switch of the index TNFi were collected for patients 
who discontinued at any point during follow-up and for 
those who discontinued by the first follow-up visit in the 
overall population and in the TNFi-naive and TNFi-ex-
perienced cohorts. Potential reasons for discontin-
uation or switch included lack of effect (inadequate 
response or failure to maintain response), side effects 
(serious, minor or fear of side effects), social reasons 
(cost, patient preference or frequency of administra-
tion), doing well (remission or similar events) and 
other reasons.
statistical analysis
Baseline patient demographics, clinical characteristics, 
disease activity measures and PROs were compared 
between TNFi-naive and TNFi-experienced patients 
and between those who continued versus discontinued 
their index TNFi by the first follow-up visit within each 
cohort using the χ2 or Fisher exact test for categorical 
variables and the two-sample t-test or Wilcoxon rank-sum 
test for continuous variables. Categorical variables were 
summarised using frequency counts and percentages; 
continuous variables were summarised by the number 
of observations, mean, SD, median and IQR. Reasons 
for discontinuation or switch of the index TNFi were 
summarised descriptively. Time to discontinuation (with 
or without switching) and time to switch of the index 
TNFi were assessed by Kaplan-Meier analysis for the 
overall population and in the TNFi-naive and TNFi-ex-
perienced cohorts. Log-rank tests were performed to test 
the equality of survivor functions between the TNFi-naive 
and TNFi-experienced cohorts. Statistical analyses were 
performed using Stata V.14.
ResulTs
Patient population and baseline characteristics
Of the 1804 patients with PsA enrolled in the Corrona 
PsA/SpA Registry, 395 initiated a TNFi during the study 
period (March 2013–January 2017); 318 had ≥1 follow-up 
visit and were included in the analyses (TNFi naive, 
n=171 (53.8%); TNFi experienced, n=147 (46.2%)) 
(figure 1). Overall, the mean (SD) age was 53.6 (13.7) 
years, 56.8% of patients were female and the majority of 
patients (90.6%) were white (table 1). TNFi-experienced 
patients had significantly longer PsA disease duration 
(mean (SD), 13.3 (10.0) vs 9.5 (9.7) years; p<0.01) and 
a higher proportion had a history of prednisone use 
(27.9% vs 17.5%; p=0.03) compared with TNFi-naive 
patients (table 1).
TNFi-naive patients had lower average lateral lumbar 
flexion (mean (SD), 13.5 (5.0) vs 21.8 (16.9) cm; p=0.04), 
lower baseline patient global assessment scores (mean (SD), 
41.1 (28.0) vs 52.2 (29.2); p<0.01) and higher EQ-5D scores 
(mean (SD), 0.74 (0.21) vs 0.70 (0.21); p=0.02) compared 
with TNFi-experienced patients; a higher proportion of 
TNFi-naive patients had minimal disease activity compared 
with TNFi-experienced patients (39.3% vs 27.4%; p=0.04) 
(table 2). TNFi-experienced patients had greater Spon-
dyloarthritis Research Consortium of Canada Enthesitis 
Index scores among those with enthesitis (mean (SD), 4.6 
(3.9) vs 2.9 (2.3)), higher pain (mean (SD), 47.3 (29.5) 
vs 40.9 (29.6)) and Health Assessment Questionnaire 
for the Spondyloarthropathies (mean (SD), 0.73 (0.66) 
vs 0.85 (0.68) scores, and a higher percentage of work 
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Table 1 Baseline demographics and clinical characteristics of TNFi-naive and TNFi-experienced patients with PsA overall 
and in those who continued versus discontinued their index TNFi by the first follow-up visit
Characteristic
Total 
population 
(N=318)
TNFi naive TNFi experienced
Overall 
(n=171)
Continued 
(n=122)
Discontinued 
(n=49)
Overall 
(n=147)
Continued 
(n=88)
Discontinued 
(n=59)
Age, mean (SD), 
years
53.6 (13.7) 53.0 (15.2) 53.6 (16.2) 51.5 (12.2) 54.3 (11.6) 54.0 (11.8) 54.9 (11.4)
Female, n (%) 179 (56.8) 94 (55.3) 64 (52.5) 30 (62.5) 85 (58.6) 45 (51.7) 40 (69.0)*
White, n (%) 288 (90.6) 159 (93.0) 112 (91.8) 47 (95.9) 129 (87.8) 78 (88.6) 51 (86.4)
BMI, mean (SD), kg/
m2
32.4 (7.6) 32.1 (8.0) 32.1 (8.1) 32.1 (8.0) 32.7 (7.1) 32.0 (7.3) 33.6 (6.8)
BMI (in kg/m2) classification, n (%) 
  Normal/
underweight 
(<25.0)
41 (13.8) 27 (17.2) 20 (17.9) 7 (15.6) 14 (9.9) 11 (13.1) 3 (5.3)
  Overweight (25.0 
to <30.0)
83 (27.9) 40 (25.5) 24 (21.4) 16 (35.6) 43 (30.5) 29 (34.5) 14 (24.6)
  Obese (≥30.0) 174 (58.4) 90 (57.3) 68 (60.7) 22 (48.9) 84 (59.6) 44 (52.4) 40 (70.2)
Insurance type, n (%) 
  Private 249 (78.5) 136 (79.5) 93 (76.2) 43 (87.8) 113 (77.4) 70 (80.5) 43 (72.9)
  Medicare 21 (6.6) 12 (7.0) 11 (9.0) 1 (2.0) 9 (6.2) 3 (3.5) 6 (10.2)
  Medicaid 21 (6.6) 12 (7.0) 9 (7.4) 3 (6.1) 9 (6.2) 6 (6.9) 3 (5.1)
  Medicare+private 21 (6.6) 8 (4.7) 7 (5.7) 1 (2.0) 13 (8.9) 8 (9.2) 5 (8.5)
  None 5 (1.6) 3 (1.8) 2 (1.6) 1 (2.0) 2 (1.4) 0 2 (3.4)
  Disease duration, 
mean (SD), years
11.2 (10.0) 9.5 (9.7) 9.7 (9.8) 8.8 (9.6) 13.3 (10.0)† 14.1 (9.4) 12.1 (10.9)
History of comorbid conditions, n (%) 
  Diabetes mellitus 43 (13.5) 21 (12.3) 15 (12.3) 6 (12.2) 22 (15.0)† 13 (14.8) 9 (15.3)
  Cardiovascular 
disease‡
45 (14.2) 18 (10.5) 15 (12.3) 3 (6.1) 27 (18.4) 17 (19.3) 10 (17.0)
  Any cancer§ 25 (7.9) 13 (7.6) 10 (8.2) 3 (6.1) 12 (8.2) 7 (8.0) 5 (8.5)
  Serious infection¶ 25 (7.9) 12 (7.0) 8 (6.6) 4 (8.2) 13 (8.8) 8 (9.1) 5 (8.5)
  Current MTX use, 
n (%)
157 (49.4) 92 (53.8) 63 (51.6) 29 (59.2) 65 (44.2) 40 (45.5) 25 (42.4)
  History of 
prednisone use, 
n (%)
71 (22.3) 30 (17.5) 22 (18.0) 8 (16.3) 41 (27.9)† 30 (34.1) 11 (18.6)
  Current prednisone 
use, n (%)
27 (8.5) 12 (7.0) 8 (6.6) 4 (8.2) 15 (10.2) 8 (9.1) 7 (11.9)
*P<0.05 for the comparison between patients who continued versus discontinued their index TNFi within the TNFi-naive or TNFi-experienced 
cohort.
†P<0.05 for the comparison between the overall populations of TNFi-naive and TNFi-experienced patients.
‡Combined histories of myocardial infarction, acute coronary syndrome, coronary artery disease, congestive heart failure, peripheral artery 
disease, cardiac revascularisation procedure, ventricular arrhythmia, cardiac arrest, unstable angina, stroke, transient ischaemic attack, 
pulmonary embolism, carotid artery disease, deep venous thrombosis or other cardiovascular event.
§Excludes non-melanoma of the skin.
¶Includes infections that led to hospitalisation or intravenous antibiotics: joint/bursa, cellulitis, sinusitis, diverticulitis, sepsis, pneumonia, 
bronchitis, gastroenteritis, meningitis, urinary tract, upper respiratory tract or infection of other specified site.
BMI, body mass index; MTX, methotrexate; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor.
time missed (mean (SD), 9.8% (24.0%) vs 2.6% (7.8%); 
p=0.03) compared with TNFi-naive patients, although only 
the difference in percentage of work time missed reached 
statistical significance (table 2).
Time to discontinuation/switch of index TnFi during total 
follow-up
The total follow-up was 579.2 person-years; the mean 
(SD) and median (IQR) total follow-up were 21.9 (9.6) 
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Figure 2 Time to discontinuation of the index TNFi in (A) the overall population and (B) TNFi-naive versus TNFi-experienced 
patients and time to switch in (C) the overall population and (D) TNFi-naive versus TNFi-experienced patients. TNFi, tumour 
necrosis factor inhibitor.
months and 23.0 (15.0) months, respectively. During 
follow-up, 75 of 171 TNFi-naive (43.9%) and 80 of 147 
TNFi-experienced (54.4%) patients discontinued their 
index TNFi, including 33 of 171 (29.3%) and 48 of 147 
(32.7%), respectively, who switched to a new biologic. 
The overall median time to discontinuation (with or 
without switching) was 24 months (95% CI 20 to 28 
months) (figure 2A). TNFi-naive patients had a signifi-
cantly longer time to discontinuation (with or without 
switching) compared with TNFi-experienced patients 
(median, 27 months (95% CI 22 to 33 months) versus 20 
months (95% CI 18 to 28 months); p=0.03) (figure 2B). 
Among those who discontinued or switched their index 
TNFi, the mean (SD) time to discontinuation or switch 
was 14.5 (8.0) months in TNFi-naive patients compared 
with 14.0 (8.9) months in TNF-experienced patients.
Due to the low number of switching events (n=81), the 
median (95% CI) time to switch to a new biologic could 
not be estimated (figure 2C). However, a long-rank test 
of the equality of survivor functions between TNFi-naive 
and TNFi-experienced patients showed that TNFi-naive 
patients had a significantly lower rate of switch compared 
with TNFi-experienced patients (p<0.01) (figure 2D). 
Among those who switched to a new biologic, the mean 
(SD) time to switch was 16.0 (8.1) months in TNFi-naive 
patients compared with 13.5 (7.5) months in TNF-expe-
rienced patients.
Of the 155 patients who discontinued or switched 
their index TNFi, 97 had ≥1 provider-reported reason 
for discontinuation or switch (TNFi naive, n=41; TNFi 
experienced, n=56). The most commonly reported 
reasons for discontinuation or switch of the index TNFi 
in both the TNFi-naive and TNFi-experienced cohorts 
were lack of efficacy (37/41 (90.2%) and 41/56 (73.2%), 
respectively) and side effects (5/41 (12.2%) and 15/56 
(26.8%), respectively) (figure 3A).
Characteristics of patients who continued versus 
discontinued index TnFi by first follow-up visit
The mean (SD) time to the first follow-up visit was 11.5 
(6.7) months (median (IQR), 10.0 (7.0) months). Of 
the 155 patients who discontinued or switched their 
index TNFi, 108 (69.7%) did so by the first follow-up 
visit, including 49 of 75 TNFi-naive (65.3%) and 59 of 
80 TNFi-experienced (73.8%) patients. In both the TNFi-
naive and TNFi experienced cohorts, a higher propor-
tion of patients who discontinued their index TNFi were 
female compared with those who continued (62.5% vs 
52.5% and 69.0% vs 51.7%, respectively), although this 
difference was only statistically significant in the TNFi-ex-
perienced cohort (p=0.04) (table 1).
TNFi-naive patients who discontinued their index TNFi 
by the first follow-up visit had significantly higher baseline 
Clinical Disease Activity Index (CDAI; mean (SD), 14.1 
(13.6) vs 9.2 (7.6); p=0.03) and Disease Activity Score in 
28 joints with C-reactive protein (DAS28-CRP; mean (SD), 
3.5 (1.7) vs 2.4 (1.0); p=0.01) scores compared with those 
who continued (table 2). TNFi-naive patients who discon-
tinued their index TNFi by the first follow-up visit also 
had a higher tender joint count (mean (SD), 7.3 (13.4) vs 
3.0 (4.9)) and lower average lateral lumbar flexion (mean 
(SD), 9.8 (13.4) vs 14.7 (4.9) cm) at baseline compared 
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Figure 3 Provider-reported reasons for discontinuation or switch of the index TNFi in (A) the overall population and (B) 
patients who discontinued by the first follow-up visit. Potential reasons for discontinuation or switch included lack of effect 
(inadequate response or failure to maintain response), side effects (serious, minor or fear of side effects), social reasons (cost, 
patient preference or frequency of administration), doing well (remission or similar events) and other reasons. Patients may 
have had more than one reason for discontinuation. TNFi, tumour necrosis factor inhibitor.
with those who continued; however, these differences did 
not reach statistical significance (table 2). Differences in 
baseline PROs were also observed: TNFi-naive patients 
who discontinued their index TNFi by the first follow-up 
visit had higher baseline pain (mean (SD), 49.5 (29.8) vs 
37.6 (28.9); p=0.02) and patient global assessment (mean 
(SD), 48.2 (27.8) vs 38.2 (27.6); p=0.04) scores compared 
with those who continued (table 2).
Among TNFi-experienced patients, those who discon-
tinued their index TNFi by the first follow-up visit had 
higher baseline physician global assessment (mean (SD), 
27.2 (24.6) vs 16.4 (16.9); p=0.01) and fatigue (mean 
(SD), 53.0 (31.0) vs 43.8 (26.5); p=0.05) scores compared 
with those who continued (table 2). Additionally, TNFi-ex-
perienced patients who discontinued their index TNFi by 
the first follow-up visit had reported a greater percentage 
of work time missed (mean (SD), 17.8% (32.4%) vs 4.5% 
(14.3%)) and work productivity loss (mean (SD), 36.0% 
(35.8%) vs 26.5% (28.5%)) compared with those who 
continued, although these differences did not reach 
statistical significance (table 2).
Of the 108 patients who discontinued or switched 
their index TNFi by the first follow-up visit, 57 had ≥1 
provider-reported reason for discontinuation or switch 
(TNFi naive, n=25; TNFi experienced, n=32). The most 
commonly reported reasons for discontinuation or switch 
in both the TNFi-naive and TNFi-experienced cohorts 
were lack of efficacy (16/25 (64.0%) and 18/32 (56.3%), 
respectively) and side effects (5/25 (20.0%) and 9/32 
(33.3%), respectively) (figure 3B).
dIsCussIOn
This real-world study using data from the US-based 
Corrona PsA/SpA Registry provides insight into the 
persistence and switching of TNFi therapy among TNFi-
naive versus TNFi-experienced patients with PsA. Patients 
who initiated their first TNFi had a longer time to discon-
tinuation and were less likely to switch TNFis compared 
with those who had previously received ≥1 TNFi. Of 
those who discontinued their index TNFi, the majority 
discontinued by the first follow-up visit. There was a 
trend towards higher baseline disease activity and worse 
PROs among patients who discontinued their index 
TNFi by the first follow-up visit compared with those who 
continued in both the TNFi-naive and TNFi-experienced 
cohorts; however, most differences did not reach statis-
tical significance. In both the TNFi-naive and TNFi-ex-
perienced groups, the primary provider-reported reasons 
for discontinuation or switch of the index TNFi were lack 
of effect and side effects, both overall and among patients 
who discontinued by the first follow-up visit.
A prior study of patients with PsA enrolled in the 
Corrona Registry showed that a higher proportion of 
biologic-naive patients were persistent on their TNFi over 
4 years of follow-up compared with biologic-experienced 
patients and that biologic-naive patients had a longer 
time to non-persistence compared with biologic-experi-
enced patients (median, 32 vs 23 months).28 Consistent 
with the results of the prior study, TNFi-naive patients in 
our study had a longer time to discontinuation (median, 
27 vs 20 months) and were less likely to discontinue 
or switch biologics compared with TNFi-experienced 
patients. However, the median time to TNFi discontinua-
tion was shorter in our study compared with the previous 
study. This difference may be due, in part, to differences 
between patient populations, including longer disease 
duration (mean, 11.2 vs 8.3 years) and higher preva-
lence of comorbidities (cardiovascular disease, 14.2% 
vs 5.4%; cancer, 7.9% vs 4.3%; diabetes mellitus, 13.5% 
vs 10.6%) in our study population compared with the 
previous study28; a previous study in the DANBIO registry 
showed that a greater burden of comorbidities was asso-
ciated with shorter TNFi persistence.29 Additionally, the 
previous study was conducted prior to the approval of 
biologics with alternative MOAs for the treatment of PsA; 
the approval of new therapies with alternative MOAs has 
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provided physicians and patients with a greater number 
of treatment options, and recently updated US and Euro-
pean guidelines for the management of PsA reflect the 
availability, efficacy and safety of these new biologics.13 14 
Current treatment guidelines also recommend using a 
treat-to-target-like strategy, when feasible, for the manage-
ment of PsA, including regular monitoring and adjust-
ment of therapy to achieve disease control.13 14 Together, 
these factors may lead to faster cycling of therapies in 
patients with an initial inadequate response to a TNFi 
in current clinical practice, possibly contributing to the 
shorter time to discontinuation observed in our study. Of 
note, the current Corrona PsA/SpA Registry collects data 
on a number of PsA/SpA-specific disease activity assess-
ments that were not available at the time of the previous 
Corrona study. Our results therefore help address a 
knowledge gap regarding PsA-specific characteristics of 
patients who continue versus discontinue TNFis.
In both the TNFi-naive and TNFi-experienced cohorts 
in our study, a higher proportion of patients who discon-
tinued their index TNFi were female compared with those 
who continued. Previous studies support the association 
of female sex with likelihood of TNFi discontinuation. 
Real-world studies in Europe and the USA have shown 
that women with PsA are more likely to discontinue TNFi 
therapy and have shorter drug survival compared with 
men.27 30–32 Additional factors previously found to be 
associated with shorter TNFi persistence and increased 
likelihood of TNFi discontinuation and switch include 
longer disease duration, the presence of other comorbid-
ities, low CRP levels (≤10 mg/L), higher disease activity 
as assessed by the CDAI, greater skin involvement and 
higher patient global assessment score.28–30 33 In our 
study population, there were no significant differences in 
disease duration or presence of comorbidities between 
patients who continued versus discontinued their index 
TNFi in the TNFi-naive or TNFi-experienced cohort. Addi-
tionally, there were no significant differences in baseline 
CRP levels; however, the overall CRP levels in all groups 
were <10 mg/L at baseline. TNFi-naive patients who 
discontinued their index TNFi by the first follow-up visit 
had significantly higher baseline CDAI and DAS28-CRP 
scores compared with those who continued. There was 
a trend towards higher CDAI and other disease activity 
measures at baseline among TNFi-experienced patients 
who discontinued their index TNFi compared with those 
who continued, although these differences did not reach 
statistical significance. Additionally, patients who discon-
tinued their index TNFi had higher pain and patient 
global assessment scores at baseline compared with those 
who continued; these differences were statistically signif-
icant in the TNFi-naive cohort. Differences in patient 
characteristics associated with TNFi discontinuation in 
our study versus previous studies may be due, in part, to 
differences among study populations with respect to age, 
disease duration, comorbidities and/or baseline disease 
activity.
This study is subject to the general limitations of real-
world observational studies. A general concern is that 
patients enrolled in registries may not be representative 
of patients seen elsewhere in general practice. Patients 
in this study are routinely seen and treated by rheu-
matologists voluntarily participating in the Corrona 
PsA/SpA Registry and may not be representative of all 
patients with PsA in the USA. In addition, the small 
sample size may have limited the ability to detect statis-
tically significant differences in baseline characteristics, 
disease activity measures and PROs between patients 
who continued versus discontinued their index TNFi by 
the first follow-up visit. Sample size considerations also 
necessitated the pooling of TNFis for analysis; thus, no 
conclusions can be drawn regarding the persistence or 
rate of switch of any specific TNFi among patients with 
PsA. Analyses of discontinuation and switching were not 
adjusted for differences in patient characteristics, and 
no conclusions can be drawn regarding characteristics 
predictive of TNFi discontinuation. Finally, only half 
of patients who discontinued their index TNFi by the 
first follow-up visit (57/108) and 60% of patients who 
discontinued overall had provider-reported reasons for 
discontinuation, which limits insight into the reasons for 
discontinuation or switch of TNFis in TNFi-naive versus 
TNFi-experienced patients.
In this real-world analysis of US patients with PsA, 
TNFi-experienced patients were more likely to discon-
tinue or switch their index TNFi and had a shorter time 
to discontinuation compared with TNFi-naive patients. 
Patients who discontinued by the first follow-up visit 
were more likely to be female compared with those who 
continued, and there was a trend towards higher disease 
activity and worse pain and patient global assessment 
scores among patients who discontinued compared with 
those who continued. The most commonly reported 
reasons for discontinuation or switch of the index TNFi 
among both TNFi-naive and TNFi-experienced patients 
were lack of effect and side effects. These results may 
help inform treatment decisions when selecting later 
lines of therapy for patients with PsA.
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